Back to News
Market Impact: 0.25
Orum Doses First Patient In Phase 1 ORM-1153 Trial For Blood Cancer
Source: Nasdaq
Healthcare & Biotech
Orum Therapeutics announced that the first patient has been dosed in a Phase 1 trial of ORM-1153 for relapsed or refractory acute myeloid leukemia. The clinical-development milestone is positive, but the report provides no efficacy or safety results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
- Supernus Pharmaceuticals stock hits 52-week low at 40.5 USD
- Top biotechnology stock pick from Guggenheim
- Liquidia shares surge 25% as settlement ends United Therapeutics litigation
- Needham raises Starling Oncology stock price target on growth outlook
- Why is Olympus stock plunging today?